Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Self-reported acute decrease in visual acuity after photodynamic therapy for age-related macular degeneration.

Franco M Recchia1, Shareen Greenbaum, Cynthia A Carvalho Recchia

  • 1Department of Ophthalmology and Associated Retinal Consultants, PC, William Beaumont Hospital, Royal Oak, MI, USA. franco.recchia@vanderbilt.edu

Retina (Philadelphia, Pa.)
|December 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CHARACTERIZING INTRAOCULAR LENS POSITION, STABILITY, AND IRIS MOBILITY IN EYES THAT HAVE UNDERGONE SUTURELESS INTRASCLERAL HAPTIC FIXATION.

Retina (Philadelphia, Pa.)·2026
Same author

POSTENDOPHTHALMITIS "BUCKET HANDLE SIGN" SIGNIFIES BULLOUS INTERNAL LIMITING LAMINA SEPARATION.

Retina (Philadelphia, Pa.)·2026
Same author

Outer Retinal Optical Coherence Tomography Changes Associated With Intraocular Silicone Oil Administration.

Journal of vitreoretinal diseases·2026
Same author

Coats-like Retinopathy Associated With 18p Deletion Syndrome.

Ophthalmic surgery, lasers & imaging retina·2025
Same author

Difluprednate for the Treatment of Postoperative Hypotony Following Complicated Retinal Detachment Surgery.

Ophthalmic surgery, lasers & imaging retina·2025
Same author

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials.

Pharmaceuticals (Basel, Switzerland)·2024
Same journal

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Retina (Philadelphia, Pa.)·2026
Same journal

ANTI-VEGF THERAPY SWITCHING RETINAL DISEASES: Characterizing Clinical Manifestations and Common Involved Genes: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

THE EFFICACY AND SAFETY OF SUBRETINAL BALANCED SALT SOLUTION INJECTION IN DIABETIC MACULAR EDEMA WITH HARD EXUDATES: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

EVALUATING CLINICAL OUTCOMES OF AMNIOTIC MEMBRANE COVERAGE COMBINED WITH EARLY VITRECTOMY IN THE MANAGEMENT OF PERFORATING GLOBE INJURIES.

Retina (Philadelphia, Pa.)·2026
Same journal

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same journal

Severe retinal non-perfusion is associated with fewer retinal lesions on ultra-wide field fundus photography in proliferative diabetic retinopathy.

Retina (Philadelphia, Pa.)·2026
See all related articles

Acute visual decrease after photodynamic therapy (PDT) for age-related macular degeneration (AMD) is uncommon, affecting about 1.2% of patients. While some vision recovery is possible, it

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Medical Treatments

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Photodynamic therapy (PDT) is a treatment for wet AMD.
  • Assessing treatment side effects is crucial for patient care.

Purpose of the Study:

  • To determine the incidence of self-reported visual acuity decrease within 7 days of PDT for AMD.
  • To describe the clinical and anatomical course of patients experiencing significant visual loss post-PDT.

Main Methods:

  • Retrospective review of 1,894 PDT treatments for 821 patients with exudative AMD.
  • Primary outcome: Snellen visual acuity change within 7 days of PDT.
  • Secondary outcomes: Fluorescein angiography (FA) and anatomical findings.

Related Experiment Videos

Main Results:

  • 32 instances (1.2% of patients) of self-reported visual change within 7 days of PDT.
  • 10 patients (0.5% of treatments) experienced a decrease of ≥2 lines of visual acuity, occurring within 3 days.
  • Subretinal hemorrhage occurred in 4 cases; FA showed choroidal hypoperfusion in 5 eyes.
  • 30% of affected patients showed visual improvement by 3 months.

Conclusions:

  • Acute visual decrease following PDT for AMD is an infrequent event.
  • Visual recovery can occur in some patients, but precise estimation is limited by sample size.